volume 91 issue 6 pages 1275-1283

BCL-2-induced glioma cell invasiveness depends on furin-like proteases

Wolfgang Wick 1
Christine Wild-Bode 2
Brigitte Frank 2
Publication typeJournal Article
Publication date2004-10-27
scimago Q1
wos Q2
SJR1.499
CiteScore9.4
Impact factor4.0
ISSN00223042, 14714159
Biochemistry
Cellular and Molecular Neuroscience
Abstract
Migration and invasion are prerequisites for the neoplastic phenotype of malignant glioma. Ectopic expression of BCL-2 enhances migration and invasion of glioma cells and promotes their synthesis of transforming growth factor-β2 (TGF-β2). We here report that BCL-2-expressing cells show enhanced expression and activity of the proprotein convertase, furin, which processes metalloproteinases (MMP) and TGF-β. Consistent with a biological role for a BCL-2-dependent increase in furin-like protease (FLP) activity, BCL-2-expressing cells exhibit enhanced MMP activity. Both a pseudosubstrate furin inhibitor, decanoyl-Arg-Val-Lys-Arg-chloromethylketone (dec-RVKR-cmk), or alpha 1-anti-trypsin Portland (PDX), a recombinant furin-inhibitory protein, suppress constitutive and BCL-2-mediated MMP activity and invasion. This inhibition is not overcome by TGF-β or hepatocyte growth factor (HGF). A neutralizing TGF-β antibody attenuates, but not abrogates, the invasive properties conferred by exogenous expression of BCL-2, whereas the MMP inhibitor o-phenantroline (o-PA) abolishes the pro-invasive action of BCL-2. Exogenous HGF results in enhanced, and expression of dominant-negative ezrin in reduced, FLP activity, and dec-RVKR-cmk blunts the HGF-induced expression of mature TGF-β2. Consequently, HGF and BCL-2 family proteins use a furin-dependent pathway to promote invasion via TGF-β and MMP in human malignant glioma cells and the pro-invasive properties of TGF-β require furin- dependent MMP activity.
Found 
Found 

Top-30

Journals

1
2
International Journal of Molecular Sciences
2 publications, 5.26%
International Journal of Cancer
2 publications, 5.26%
Cancer Research
2 publications, 5.26%
Aging
1 publication, 2.63%
Oncotarget
1 publication, 2.63%
Molecular Medicine Reports
1 publication, 2.63%
International Journal of Oncology
1 publication, 2.63%
Clinical Medicine Insights: Oncology
1 publication, 2.63%
Frontiers in Immunology
1 publication, 2.63%
Frontiers in Cell and Developmental Biology
1 publication, 2.63%
Medical Oncology
1 publication, 2.63%
Investigational New Drugs
1 publication, 2.63%
PLoS ONE
1 publication, 2.63%
Neoplasia
1 publication, 2.63%
Journal of Immunological Methods
1 publication, 2.63%
Journal of Clinical Neuroscience
1 publication, 2.63%
Journal of Ethnopharmacology
1 publication, 2.63%
International Journal of Biological Macromolecules
1 publication, 2.63%
Trends in Pharmacological Sciences
1 publication, 2.63%
European Journal of Pharmacology
1 publication, 2.63%
Journal of Cellular Biochemistry
1 publication, 2.63%
Medicinal Research Reviews
1 publication, 2.63%
Journal of Magnetic Resonance Imaging
1 publication, 2.63%
Carcinogenesis
1 publication, 2.63%
APMIS
1 publication, 2.63%
Clinical Cancer Research
1 publication, 2.63%
Genes and Development
1 publication, 2.63%
Oncology Letters
1 publication, 2.63%
Oncology Reports
1 publication, 2.63%
1
2

Publishers

1
2
3
4
5
6
7
Elsevier
7 publications, 18.42%
Wiley
6 publications, 15.79%
Spandidos Publications
4 publications, 10.53%
Springer Nature
3 publications, 7.89%
American Association for Cancer Research (AACR)
3 publications, 7.89%
Impact Journals
2 publications, 5.26%
MDPI
2 publications, 5.26%
Frontiers Media S.A.
2 publications, 5.26%
Oxford University Press
2 publications, 5.26%
SAGE
1 publication, 2.63%
Public Library of Science (PLoS)
1 publication, 2.63%
Cold Spring Harbor Laboratory
1 publication, 2.63%
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 2.63%
1
2
3
4
5
6
7
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
38
Share
Cite this
GOST |
Cite this
GOST Copy
Wick W. et al. BCL-2-induced glioma cell invasiveness depends on furin-like proteases // Journal of Neurochemistry. 2004. Vol. 91. No. 6. pp. 1275-1283.
GOST all authors (up to 50) Copy
Wick W., Wild-Bode C., Frank B., Weller M. BCL-2-induced glioma cell invasiveness depends on furin-like proteases // Journal of Neurochemistry. 2004. Vol. 91. No. 6. pp. 1275-1283.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1111/j.1471-4159.2004.02806.x
UR - https://doi.org/10.1111/j.1471-4159.2004.02806.x
TI - BCL-2-induced glioma cell invasiveness depends on furin-like proteases
T2 - Journal of Neurochemistry
AU - Wick, Wolfgang
AU - Wild-Bode, Christine
AU - Frank, Brigitte
AU - Weller, M
PY - 2004
DA - 2004/10/27
PB - Wiley
SP - 1275-1283
IS - 6
VL - 91
PMID - 15584904
SN - 0022-3042
SN - 1471-4159
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2004_Wick,
author = {Wolfgang Wick and Christine Wild-Bode and Brigitte Frank and M Weller},
title = {BCL-2-induced glioma cell invasiveness depends on furin-like proteases},
journal = {Journal of Neurochemistry},
year = {2004},
volume = {91},
publisher = {Wiley},
month = {oct},
url = {https://doi.org/10.1111/j.1471-4159.2004.02806.x},
number = {6},
pages = {1275--1283},
doi = {10.1111/j.1471-4159.2004.02806.x}
}
MLA
Cite this
MLA Copy
Wick, Wolfgang, et al. “BCL-2-induced glioma cell invasiveness depends on furin-like proteases.” Journal of Neurochemistry, vol. 91, no. 6, Oct. 2004, pp. 1275-1283. https://doi.org/10.1111/j.1471-4159.2004.02806.x.